Vertex Pharmaceuticals Incorporated
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT07022119
A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 136
- Registration Number
- NCT07010406
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
- First Posted Date
- 2025-04-14
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 36
- Registration Number
- NCT06926621
- Locations
- π¦πΊ
Wesley Research Institute, Auchenflower, Australia
π¦πΊNeuroscience Clinical Trials Unit, Alfred Brain, Melbourne, Australia
π¨π¦University of Ottawa, Ottawa, Canada
A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 100
- Registration Number
- NCT06887972
- Locations
- πΊπΈ
Atlanta Center for Medical Research, Atlanta, Georgia, United States
πΊπΈHD Research LLC | First Surgical Hospital, Bellaire, Texas, United States
πΊπΈMemorial Hermann Village, Houston, Texas, United States
A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 200
- Registration Number
- NCT06887959
- Locations
- πΊπΈ
Cooper University HealthCare (CUH), Camden, New Jersey, United States
πΊπΈScottsdale Clinical Trials, Scottsdale, Arizona, United States
πΊπΈWoodland International Research Group, Little Rock, Arkansas, United States
A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose
- Conditions
- Pain
- Interventions
- Drug: 14C-VX-993
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 8
- Registration Number
- NCT06886269
- Locations
- πΊπΈ
Celerion - Lincoln, Lincoln, Nebraska, United States
A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 68
- Registration Number
- NCT06861413
- Locations
- πΊπΈ
Celerion - Tempe, Tempe, Arizona, United States
A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 10
- Registration Number
- NCT06834009
- Locations
- πΊπΈ
Senopsys, LLC, Woburn, Massachusetts, United States
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
- Conditions
- Type 1 DiabetesKidney Transplant
- Interventions
- Biological: Biological/Vaccine
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 10
- Registration Number
- NCT06832410
- Locations
- πΊπΈ
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈUniversity of Pittsburgh Medical Center Montefiore, Pittsburgh, Pennsylvania, United States
π¨π¦Toronto General Hospital (TGH), Toronto, Canada
Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 50
- Registration Number
- NCT06820307
- Locations
- πΊπΈ
Celerion - Tempe, Tempe, Arizona, United States